NCI panel recommends Celsion's Phase III ThermoDox HEAT Study as Priority Clinical Trial for HCC

Celsion Corporation (Nasdaq: CLSN) announced today that the consensus recommendations of the National Cancer Institute (NCI) Clinical Trials Planning Meeting (CTPM) for Hepatocellular Carcinoma have been released and published in the August 2010 issue of Journal of Clinical Oncology, the official publication of American Society of Clinical Oncology (ASCO). In addition to evaluating the current standard of care, the NCI panel also recommended Celsion's Phase III ThermoDox ® HEAT Study as a Priority Clinical Trial for HCC.

"We are pleased this prominent panel of experts at the NCI Clinical Trials Planning Meeting have recognized the importance of our Phase III HEAT Study," stated Michael H. Tardugno, President and Chief Executive Officer of Celsion. "Upon completion of the trial and eventual marketing approval, ThermoDox plus RFA will provide an additional therapeutic option for patients afflicted with HCC, a dreadful disease with high unmet medical need."   Dr. Nicholas Borys, Chief Medical Officer of Celsion Corporation commented, "This JCO article also reinforces the global importance of new therapies for HCC, and highlights the prominence of the ThermoDox program, which is now over 2/3rds enrolled in 75 global sites and 11 countries."

Celsion's global Phase III ThermoDox study for primary liver cancer plans to enroll 600 patients and is being conducted under a FDA Special Protocol Assessment (SPA). The study is designed to evaluate the efficacy of ThermoDox in combination with radiofrequency ablation (RFA) when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival. Additional information on the Phase III ThermoDox clinical study may be found at www.clinicaltrials.gov.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Inequalities in green space linked to preventable deaths in urban areas